Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.
It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4]
External links
References
- Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II Mol. Genet. Metab., 2007^
- Drug approved to treat rare but potentially deadly disease retrieved 2011-04-29^
- Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010^